Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. In this ...

The funding includes contributions from new investors such as Baylor College of Medicine and the Brain Tumor Investment Fund.

The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel ...

The therapy is called autologous transplant ... The other form of blood stem cell transplantation — called “allogeneic,” meaning that the cells come from another person — has long been recognized as a ...

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has achieved a major milestone in the fight against acute myeloid leukemia ...

Safety and activity of programmed cell death-1 gene knockout engineered t cells in patients with previously treated advanced esophageal squamous cell carcinoma: An open-label, single-arm phase I study ...

At this year’s American Society of Clinical Oncology (ASCO) meeting, autologous cancer therapeutics ... for consolidation therapy to treat mantle cell lymphoma (MCL), which has a median survival ...

The majority of autologous CAR-T cell therapies involve ... Fate Therapeutics is at the forefront of programmed cellular immunotherapy developments designed to treat cancer and immune disorders.

Due to financial, logistical, and regulatory barriers, only two in 10 patients eligible for CAR T-cell therapy in the US ...

Now a new approach using donor cells brings the hope of giving off-the-shelf CAR T cell immunotherapy to patients in as little as five days. Conventional autologous CAR T therapy requires cells to be ...